Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Danshen Dripping Pills for coronary microcirculation in diabetes
NCT05295329Unknown
- Sponsor
- Ruijin Hospital
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Compound Danshen in coronary microvascular disease (CMD) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Microcirculation Resistance Index improvement at 3 months. Status: unknown.
02
Drugs
Compound Danshen
03
Conditions
coronary microvascular disease (CMD)
Beyond the preview
Go deeper on NCT05295329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295329.